Copyright
©The Author(s) 2017.
World J Hepatol. Apr 18, 2017; 9(11): 544-550
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Table 5 Causes of discontinuation and numbers of patients in whom the study drugs were discontinued due to adverse events in the elderly and non-elderly groups
Elderly patients | Non-elderly patients |
16 w Malaise, Anorexia1 | 18 w Elevation of ALT1 |
6 w Malaise, Anorexia1 | 6 w Elevation of ALT1 |
6 w Elevation of ALT1 | 2 w Pyrexia1 |
8 w Elevation of ALT1 | 3 w Pyrexia |
3 w Pyrexia | 13 w Sepsis due to hemolytic |
4 w Cough | streptococcus1 |
18 w Development of HCC1 | 18 w Abdominal fullness1 |
2 w Elongation of PT | |
3 w Elevation of total bilirubin1 | |
18 w Development of HCC1 | |
Total 7/56 (12.5%) | 9/141 (6.4%) |
- Citation: Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol 2017; 9(11): 544-550
- URL: https://www.wjgnet.com/1948-5182/full/v9/i11/544.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i11.544